Tocilizumab discontinuation after remission achievement in patients with adult-onset Still's disease.

ABSTRACT:

Objectives

Tocilizumab, an IL-6 inhibitor, has been proven effective in patients with adult-onset Still's disease (AOSD). This study aimed to clarify whether tocilizumab can be discontinued after achieving remission and to identify factors relevant to its successful discontinuation.

Methods

Consecutive patients with AOSD diagnosed according to Yamaguchi's criteria from April 2012 to July 2022, who were treated with tocilizumab, were retrospectively reviewed.

Results

Forty-eight patients with AOSD treated with intravenous tocilizumab, with sufficient information, were included. Thirty-eight patients (79.2%) achieved remission after 6 months of tocilizumab treatment, 12 of whom discontinued tocilizumab during remission. Within 1 year after tocilizumab discontinuation, s

SUBMITTER: Tamai H 

PROVIDER: S-EPMC11879347 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature